Intensity Therapeutics Inc. (NASDAQ:INTS) Given Average Rating of “Moderate Buy” by Analysts

Intensity Therapeutics Inc. (NASDAQ:INTS) has been given an average rating of “Moderate Buy” by the five analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $7.00.

A number of research firms recently issued reports on INTS. Benchmark reiterated a “speculative buy” rating on shares of Intensity Therapeutics in a research report on Wednesday, May 20th. Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th. HC Wainwright lifted their price target on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st.

Intensity Therapeutics Trading Up 2.5%

NASDAQ INTS opened at $4.10 on Friday. The stock has a market capitalization of $13.37 million, a P/E ratio of -1.15 and a beta of 2.76. The business has a 50 day simple moving average of $4.40 and a 200 day simple moving average of $5.05. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00. Intensity Therapeutics has a one year low of $3.51 and a one year high of $43.50.

Intensity Therapeutics (NASDAQ:INTS) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.24). Research analysts expect that Intensity Therapeutics will post -2.64 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LLC acquired a new stake in Intensity Therapeutics in the fourth quarter valued at approximately $41,000. Geode Capital Management LLC raised its position in shares of Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after purchasing an additional 201,357 shares during the period. State Street Corp lifted its holdings in shares of Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Intensity Therapeutics in the 4th quarter worth $26,000. Finally, Mesirow Financial Investment Management Inc. grew its position in Intensity Therapeutics by 25.5% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after purchasing an additional 51,000 shares during the period. Institutional investors own 3.74% of the company’s stock.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.